World Journal of Advanced Research and Reviews
eISSN: 2581-9615 CODEN (USA): WJARAI
Cross Ref DOI: 10.30574/wjarr
Journal homepage: https://wjarr.com/

(Review Article)

Deep learning, Artificial Intelligence and machine learning in cancer: Prognosis, diagnosis and treatment

Temitope Oluwatosin Fatunmbi [1, *], Andrew Ricardo Piastri [2] and Frederick Adrah [3]

[1] Temitope Oluwatosin Fatunmbi, Hustle, Victoria Island, Lagos, Nigeria.
[2] Andrew Ricardo Piastri, Rhoda, Colorado Springs, Colorado, Nigeria.
[3] Frederick Adrah, Unilever, London, London, United Kingdom.

World Journal of Advanced Research and Reviews, 2022, 15(02), 725–739

Publication history: Received on 14 July 2022; revised on 21 August 2022; accepted on 24 August 2022

Article DOI: https://doi.org/10.30574/wjarr.2022.15.2.0359

Abstract

Thus, over the past years, the progress in AI, especially in machine learning and deep learning, has affected the area of oncology. It is in this context that this paper reviews the different changes in technologies for cancer prognosis, diagnosis, and treatment. Some of the ways that AI is helping improve cancer diagnosis and treatment are in the analysis of large clinical and genetic data to provide better forecast accuracy of cancer outcomes, the detailed image analysis to aid early cancer diagnosis, and the use of population, patient, and clinical data to create a custom-made treatment plan. For instance, ML performs well in prognostic evaluations where the algorithm tries to predict diseases' progress and patients' survival since it can recognize specific patterns in large databases; on the other hand, DL, particularly CNNs, are precise in interpreting medical images for early diagnosis. Also, AI assists in the application of enhanced therapies for genetic mutations as a form of precision medicine. During treatment strategy development, AI supports oncologists in determining the appropriate radiation doses and the proper combination of drugs; robotic systems increase the accuracy of operations due to AI. However, there is still information privacy and protection, algorithm and model bias, and implementation of AI applications in the context of clinical health care. These issues require special attention for the future development and adoption of AI in oncology. The present uses, advantages, and prospects of AI, ML, and DL in cancer treatment have been described in this paper, along with the focus on the capability of the interventions to transform the course of therapy and actual patient experience.

Keywords: Artificial Intelligence; Machine Learning; Predictive Analysis; Deep Learning; Generative Adversarial Networks

1. Introduction

Though it is constraining, cancer more than doubles its toll on human lives and contributes to the diagnosis of millions of new cases every year. Due to the nature of cancer, its prognosis, diagnosis, and treatment are very challenging due to the varied and diversified presentation of this disease. It is critical to note that traditional approaches to patient care and treatment are sometimes lacking in delivering accurate and individual patient-centered care. Over the years, advances in technology, particularly the integration of artificial intelligence, have expanded opportunities in these aspects. One of the branches of AI, namely machine learning (ML) and, in particular, deep learning (DL), has turned out to be valuable in oncology.

- **Artificial Intelligence in Healthcare:** AI is the branch of computer sciences that deals with replicating human minds in order to solve tasks in a sophisticated manner. AI systems in the context of healthcare are used to define patterns, draw conclusions, and make suggestions concerning the diagnosis and treatment of diseases.

* Corresponding author: Temitope Oluwatosin Fatunmbi

These capabilities are most useful where timely and accurate information is a potent weapon in the fight against the disease as regards oncology.

- **Machine Learning and Deep Learning:** ML covers the AI section, where algorithms are designed in such a way that a computer is able to learn from data. It has enabled the creation of models that can forecast results or categorize data depending on its characteristics as a learning process. Another branch of ML, namely, deep learning, or DL for short, employs neural networks with many layers to work with and interpret the information. There are neural network structures that simulate the structure of the brain and are very efficient at image and speech recognition.

1.1. Prognosis, Diagnosis, and Treatment: The application of ML and DL in cancer care spans several critical areas:

- **Prognosis:** It is crucial that the clinicians be able to identify the probable pattern and prognosis of the disease so that the management plan can be made appropriately. The specific information in this regard is that ML models can process the data of patients with cancer or with a predisposition to the disease, as well as clinical and genetic data and lifestyle, to estimate the further development of the oncological process and to predict patient survival.
- **Diagnosis:** Getting a diagnosis in the early stages is essential and contributes immensely to the treatment outcomes of the condition. The use of DL techniques, especially CNNs, has been proven to be very effective in understanding medical images, for example, MRI and CT scans, and pinpointing cancerous lesions with high accuracy.
- **Treatment:** AI assists in the creation of individual treatment plans as the database of patient information is examined to identify the most effective interventions. This entails identifying the best chemotherapy regimens, determining the determining the prognosis for targeted treatment, and helping in preparation for treatment through robotic surgeries.
- **Significance and Objectives:** AI, ML, and DL's extended application in oncology may offer a stronger chance of improving prognosis, diagnostics, and treatment in cancer. Therefore, the purpose of this paper is to discover the availability of AI technologies in cancer treatment systems today, evaluate the use of AI technologies for prognosis, diagnosing, and treating cancer, and discuss the related issues and potential developments in cancer care with AI technologies.

As the statistics of cancer growth for the coming years experience a constant increase all over the world, the usage of modern AI solutions may be considered the key to enhancing treatment outcomes. It aims to show how, through the application of advanced ML and DL approaches, healthcare providers can increase the level of accuracy and outcomes in cancer diagnosis and treatment, which in turn means improving patients's prognosis, detection at an early stage, and optimal treatment options.

2. Understanding the Technologies

The integration of technologies such as deep learning, artificial intelligence, and machine learning can revolutionize cancer care, hence the need to understand what these technologies are all about. To this end, the following section describes in detail AI, ML, and DL, how they function, and their application to oncology.

2.1. Artificial Intelligence (AI)

2.1.1. Definition and Scope

AI can be understood as the ability of a computer to demonstrate human-like intelligence in various operations or processes it undertakes. Tasks such as thinking, studying, solving a problem, and perceiving and comprehending languages are among them. AI systems can be generally classified into two types: firstly, the first kind of AI is known as the narrow AI, which is designed specifically for a particular purpose, for example, image recognition; secondly, the second type of AI is known as the general AI; this type of AI is programmed to do any task that a human can do.

2.1.2. Mechanisms

AI systems rely on explicit mathematical models together with or in lieu of a processor that sieves through significantly large amounts of data in order to identify the right correlations and patterns that lead to the right effects. They are designed with objectives that can be enhanced over time using information, feedback, and experience.

2.1.3. Relevance to Oncology

Specifically, in oncology, AI helps to sort out large data sets such as patients' medical data and genomic data, as well as clinical trial data for the diagnosis, treatment, and prognostication of cancer. AI helps in the recognition of structures that might be suspected of being cancer-related and speeds up and optimizes the overall clinical decision-making process.

2.2. Machine Learning (ML)

2.2.1. Definition and Scope

ML is a subfield of AI that deals with learning or training algorithms that are required for decision-making based on information. Unlike ordinary programming, where the programs are coded and the computer is instructed what to do, ML systems learn from samples.

2.2.2. Types of ML

- Supervised Learning: The algorithm learns from labeled data, which implies that the input data is labeled for the right output. This type of learning is applicable for cases related to classification, like cancer and non-cancer cells, or regression, like the growth of a tumor.
- Unsupervised Learning: The algorithm is tested on unsupervised data, and it needs to identify relations and dependencies in the given data. This type of learning is appropriate for clustering (i.e., dividing the patients into groups by their genetic features) and anomaly detection (i.e., finding non-typical values of cancer indicators).
- Semi-supervised Learning: A blend of labeled and unlabeled data increases the efficiency of learning with much less labeled data than is used in supervised learning.

Reinforcement learning means that the algorithm changes its behavior by performing actions and becoming modified based on feedback in the form of unrewarding. It is particularly applied in decision-making schemas, which include issues such as designing optimal treatment regimes.

2.2.3. Mechanisms

ML algorithms build up models with the use of training data, and these models are then used to make some predictions or decisions. After creating the models, there is a step known as validation, where the development and accuracy of the models are checked.

2.2.4. Relevance to Oncology

ML is extensively used in oncology for tasks such as:

- **Predictive Analytics:** Using the historical analysis of cases to predict the probability of cancer reoccurrence and the patient's survival.
- **Personalized Medicine:** Socio-demographic and clinical characteristics as a measure for finding out the best treatment regimes.
- **Risk Stratification:** Proper grouping of the patients with varying levels of risks in order to receive treatment according to their order of priority.

2.3. Deep Learning (DL)

2.3.1. Definition and Scope

Building on the above knowledge, ML has a subcategory known as deep learning (DL), which entails neural networks with several layers to examine different aspects of data. These networks are basically a model of the brain's neurons to analyze the given large and complex datasets with high precision.

2.3.2. Types of neural networks

- **Convolutional Neural Networks (CNNs):** Originally, this board was designed to be applied for image and spatial data analysis. This has mostly been seen in medical imaging, where CNNs have helped in detecting tumors in MRI and CT scans.
- **Recurrent Neural Networks (RNNs):** best when the variables are sequential and generate sequences such as time sequences. RNNs are applied in the study of genetics and patients' records at different times.

- **Generative Adversarial Networks (GANs):** It consists of two networks: a generator and a discriminator responsible for generating new data and verifying it. It is employed in data augmentation, for creating artificial medical images required in research, and for training.

2.3.3. Mechanisms

DL models contain several nodes called neurons arranged in layers, and every subsequent layer derives higher-level features from the inputs. Patricia, the learning process that is used to weigh these connections is done in such a way that seeks to bring as close to zero as possible the errors made on an output, which is referred to as backpropagation.

2.3.4. Relevance to Oncology

DL has revolutionized several aspects of cancer care:DL has revolutionized several aspects of cancer care:

- Medical Imaging: CNNs have proved superior to the conventional approaches to lesion detection in radiological and pathological images.
- Genomic Analysis: DL models examine small samples of genomic data to detect mutations and estimate the patients' reaction to the targeted treatment.
- Natural Language Processing (NLP): Utilizing aspects of data mining to obtain pertinent information from clinical notes and other scholarly articles to enhance evidence-based practice.

The issues related to AI, ML, and DL need to be understood in order to grasp their possibilities in cancer treatment. Information technologies allow for massive and diverse amounts of data, leading to more accurate diagnoses, early diagnosis, and an individual approach to therapy. I expect that the utilization of AI in the clinic will further improve cancer care as the fields of research and development of these technologies progress in the future.

3. Prognosis

Predicting the probable course and result of the disease, including the chance of progression, recurrence, and patient survival, is known as the prognosis of cancer. Precise prognostic evaluations are essential for informing treatment choices and enhancing patient results. Artificial intelligence (AI), machine learning (ML), and deep learning (DL) have brought forth potent instruments that improve the precision and dependability of cancer prognosis. The uses, advantages, and difficulties of these technologies in cancer prognosis are examined in this section.

3.1. Predictive Analytics

3.1.1. Definition and Scope

Statistical modeling is a key component of predictive analytics that entails making forecasts through analyzing history and current data. When applied to cancer prediction, the ability of ML models to identify relevant patterns in patient data allows for the determination of the disease's progression, relapse status, and survival probability.

3.1.2. Applications

- **Breast Cancer:** Scientists have designed the ML models for estimating breast cancer relapse based on patients's mammography, genomic profiling, and clinical history. These models aid in the identification of those patients most probable to experience reoccurrences so as to take preventive measures as soon as possible.
- **Prostate Cancer:** AI applications in oncology involve the use of models that anticipate the course of prostate cancer by assessing the patient's PSA, biopsy findings, and imaging studies. These predictions help in the management of the patients as the clinician decides whether the patient requires more intensive therapy or if he should remain more passive with less intervention.
- **Lung Cancer:** The DL models perform computational analysis of the CT scans and patient data in order to estimate the probability of lung cancer recurrence. These help an oncologist prescribe when a patient should come back for a review or to develop a plan for dealing with the cancer.

3.1.3. Benefits

- **Personalized Prognosis:** ML models give customized risk checks by analyzing each patient's features; thus, better treatment strategies are offered.
- **Early Intervention:** With predictive analytics, patients most likely to develop recurrences or progressions can be easily recognized early enough, leading to an enhancement in survival rates.
- **Data-Driven Decisions:** The use of AI-driven prognostic models specifically decreases the intuitive decision-making process, which is based on parliamentary judgment.

3.1.4. Challenges

- **Data Quality:** As with any learning mechanism, the reliability of an ML model is contingent on the raw data fed into the structure. Absence or fluctuating data are not good for the accurate working of the models and the outcomes that are derived from them.
- **Interpretability:** The most complex models, such as machine learning, specifically deep learning, come with the major disadvantage of interpretation; hence, clinicians will not understand the underpinnings of predictions made from such techniques.
- **Generalizability:** If specifically trained, the model cannot execute well when it is applied to other populations or clinical settings.

3.2. Survival Analysis

3.2.1. Definition and Scope

Statistical techniques for assessing the anticipated time until one or more events of interest—such as a disease's progression or death—are used in survival analysis. By adding a variety of variables and spotting intricate patterns, DL and ML techniques improve survival analysis.

3.2.2. Applications

- **Kaplan-Meier Estimates:** Standard techniques of survival analysis such as Kaplan Meier are complemented by ML to consider other factors of the patients to provide better and precise survival rates.
- **Cox Proportional Hazards Model:** In its basic form, the Cox proportional hazards model is subsequently generalized to allow for nonlinear interaction and high-dimensional data so as to yield more accurate survival prognosis.
- **DeepSurv:** A Survival model that has been based on the DL model with neural networks to consider the survival of people. DeepSurv has been used in breast, lung, and prostate cancer cases and yields better predictive results than the conventional approaches.

3.2.3. Benefits

- **Enhanced Accuracy:** Compared to OLS, these interactions ML and DL models make for the development when predicting survival.
- **Dynamic Predictions:** These models have the ability to change the prognosis of patients as fresh data is input and are able to give real time prognosis results.
- **Comprehensive Analysis:** Mainly, due to the use of a large number of variables, ranging from the genomic ones all the way up to the clinical and lifestyle factors, the picture of the patient's prognosis is more complete.

3.2.4. Challenges

- **Computational Complexity:** The major challenge pertinent to the use of DL models is the large amount of computational power needed for training and validation purposes within the context of most healthcare organizations.
- **Model Validation:** Reliability of the prognostic models being made for different patient populations and various clinical settings is perhaps important than consistency given that a robust model can be a one-stop tool in providing the necessary prognosis.
- **Integration with Clinical Practice:** There are four general strategies to integrate the results of ML-driven survival analysis into real-world clinical practice: Changes in workflow, Adaptation or extension of currently existing methods, new methods from outside of clinical practice, and active training of clinicians incorporating the results of ML-driven survival analysis.

3.3. Risk Stratification

3.3.1. Definition and Scope

Using risk assessment to divide patients into groups according to their chance of a specific result is known as risk stratification. Risk stratification is improved by AI and ML algorithms' analysis of intricate datasets and detection of minute risk details.

3.3.2. Applications

- **Breast Cancer:** The ML models of the prognosis of breast cancer divide a set of patients into low-risk, medium-risk, and high-risk categories depending on the size of the tumor, lymph node involvement, and genetic markers. These stratifications determine the treatment, for instance, chemotherapy, that is to be administered.
- **Colorectal Cancer:** Histopathological images along with clinical information of colorectal cancer patients are used by AI algorithms to estimate the risk groups and ensure the right treatment trail.
- **Leukemia:** The ML algorithm saves patients' genomic information to find those who have high-risk leukemia and should be offered intensive treatment or enrollment in clinical trials.

3.3.3. Benefits

- **Targeted Interventions:** Risk stratification in patients is useful in identifying high-risk patients who would benefit from interventional approaches and therefore enhances patients' care and effective use of resources.
- **Patient Management:** The approach simplifies follow-up and monitoring by differentiating patients' levels of risk so that recurrence or progression can easily be detected.
- **Precision Medicine:** Risk assessment by AI helps to achieve precision medicine by determining which patients will benefit from a certain therapy or intervention.

3.3.4. Challenges

- **Bias and Fairness:** If trained on improper biases, there exist cases in which the disparities in risk assessment and proposed treatments are significant.
- **Ethical Considerations:** Thus, it can be inferred that the responsible and evidence-based practices of AI-enabled risk stratification are imperative to ensuring patient trust and healthcare equity.
- **Data Integration:** Combining usually disparate data types that include genomic, clinical, and lifestyle data adds complexity to developing ML models because of differences in the format and quality of the data.

In cancer prognosis, AI, ML, and DL technologies have improved analysis effectiveness in terms of prognosis predictive techniques, survival rates, and risk categorization. Such tools help in offering a unique prognosis, and thus the right treatment plans and interventions are made at the correct time. Nevertheless, the issues concerning data quality, model explanations, and application of the technologies in clinical practice settings should be resolved to optimize the effectiveness of the technologies in elevating cancer experiences. This obviously means that as new research and development is carried out, prognosis models enhanced through artificial intelligence will be of more significant importance to oncology, hence leading to better patient survival.

4. Diagnosis

The identification of cancer, or accurate diagnosis as well as timely diagnosis, is one of the critical steps in cancer control. The introduction of AI, ML, and DL into cancer diagnosis has significantly improved the accuracy of identifying cancer in its early stages, distinguishing between different cancer types, and understanding the clients' condition in a way that helps develop individualized treatment strategies. This section looks at the uses, advantages, and disadvantages of these technologies in cancer diagnosis.

4.1. Image Analysis

4.1.1. Definition and Scope

Image analysis is the process of assessing medical images to diagnose the disease and find out the presence of a tumor or lesion. With the use of extensive images, AI, mainly the DL models, has dramatically transformed the evaluation of informative diagnostic imaging data.

4.1.2. Applications

- **Mammography:** DL models and, more notably, CNN have been observed to demonstrate impressive accuracy in identifying breast cancer on mammography. They can recognize several patterns that can hint at early-stage cancer, such as those that appear as calcifications.
- **Histopathology:** By using histopathological slides, cancerous cells are diagnosed through the assessment of the AI algorithms. Thus, the DL models can accurately classify tissues having samples and distinguish between benign and malignant cells and even specific subtypes of cancer.
- **Radiology:** In the field of CT/MRI, the DL models can also distinguish and outline tumors in vital organs like the lung, liver, and brain. These models help the radiologist outline cancerous lesions that even might not be seen by the naked eye.

4.1.3. Benefits

- **Increased Accuracy:** DL models often outperform human radiologists in detecting cancer, reducing the likelihood of missed diagnoses.
- **Consistency:** AI models provide consistent interpretations of imaging data, eliminating variability in readings by different radiologists.
- **Efficiency:** Automated image analysis speeds up the diagnostic process, allowing for quicker decision-making and reducing patient anxiety.

4.1.4. Challenges

- **Data Quality:** The accuracy of DL models depends on the quality of the training data. Poor-quality images or incomplete datasets can affect model performance.
- **Interpretability:** Understanding the decision-making process of complex DL models can be challenging, making it difficult for clinicians to trust and validate the results.
- **Integration:** Integrating AI tools into existing diagnostic workflows requires significant changes in infrastructure and training for healthcare professionals.

4.2. Early Detection

4.2.1. Definition and Scope

Disease detection at a preliminary stage means that the condition can be treated at the initial stage when it has not developed to the advanced stage. AI and ML models help in increasing the chances of early detection using biomarkers, genetic information, and other indices of cancer.

4.2.2. Applications

- **Liquid Biopsy:** Machine learning models used to identify cancer at an early stage measure CTCS and cfDNA in the patient’s blood. These are some of the tests that do not require any form of invasion but offer significant information concerning the existence and type of cancer.
- **Genetic Screening:** The AI algorithms study the mutations and variations of the genes that are at risk of causing cancer. It is also useful for defining the clients who should use the preventive steps or screenings more often.
- **Biomarker Analysis:** DL models process biomarker data and try to find a correlation with early cancer stage indication. This ranges from the genetic sequencing of proteins, metabolites, and other molecular factors in blood or tissue.

4.2.3. Benefits

Non-Invasive Testing: Techniques like liquid biopsies, which are AI-enabled, are less intrusive than, for instance, tissue biopsy and hence pose minimal discomfort to patients.

- **High Sensitivity:** It also proves that ML models can easily ‘see’ small variations in biomarker levels that are indicative of the early presence of cancer.
- **Personalized Screening:** AI algorithms can also personalize the screening programs depending on risk factors; this makes certain patients get the attention they require.

4.2.4. Challenges

- **False Positives/Negatives:** Striking for high sensitivity without compromising specificity is rather complex; enhancing sensitivity often means raising the possibility of false positive results, which means a lot of unnecessary interventions as well as stress on the part of the patient.
- **Standardization:** According to the present findings, it is imperative that benchmark procedures are put in place for early assessment techniques leveraging artificial intelligence.
- **Regulatory Approval:** The process of acquiring regulatory approval to market new diagnostic applications based on artificial intelligence involves rather cumbersome validation and clinical trials.

4.3. Precision Medicine

4.3.1. Definition and Scope

Precision medicine can be defined as the concept of providing medicine based on the specific needs of a particular patient, especially the genetic needs of the patient. Genetic and molecular analysis involving AI and ML is used in developing treatment strategies for the patient.

4.3.2. Applications

- **Genomic Analysis:** The AI algorithms then process and dissect genomic sequencing data to flag out mutations and alterations possessed by individuals that may correspond to the particular types of cancer. This information helps in the choice of specific therapeutic interventions that are likely to yield better outcomes.
- **Predictive Modeling:** Using an individual patient’s genomic and molecular characteristics, the ML models estimate each patient’s prognosis after the onset of a disease and his or her reaction to various therapies. This is useful in identifying the most suitable therapy to prescribe and one that has minimal adverse effects on the patient.
- **Drug Response:** DL models apply analysis to the data generated through clinical trials and patients’ records to estimate which patients would be most likely to benefit from new or existing drugs. This in turn enhances the formulation of unique treatment regimens for patients suffering from the diseases.

4.3.3. Benefits

- **Targeted Therapies:** It offers the chance of using chemo-therapeutic agents that selectively go and kill cancer cells without harming healthy cells, thus cutting the adverse effects and enhancing the combination.
- **Optimized Treatment Plans:** The analysis performed with the help of artificial intelligence can contribute to the development of treatment strategies that take into account such features of oncological diseases as the type of cancer, the location of the tumor, and the characteristics of the tumor tissue.
- **Reduced Trial and Error:** AI in this case helps in minimizing the time spent guessing which drugs will be effective for those needed to discover the most efficient ways to cure a disease, hence expediting patient care.

4.3.4. Challenges

- **Data Complexity:** The processes of analyzing genetic and molecular data are much more intricate, and it is essential to use complicated algorithms and a great deal of computing resources.
- **Data Privacy:** The privacy of patient genetic data is very important since the leakage of any genetic data could have stringent ethical and legal repercussions.
- **Access to Technology:** Preventing disparities in cancer care requires that access to the novel tools of precision medicine be made uniformly possible by AI.

Accuracy, efficiency, and customization of diagnostic processes have all increased dramatically with the integration of AI, ML, and DL in cancer diagnosis. Better patient outcomes are ultimately the result of these technologies, which also promote precision medicine and allow for early identification and enhanced picture analysis. To fully exploit these technologies' potential, however, issues pertaining to data quality, model interpretability, and integration into clinical processes need to be resolved. It is anticipated that as technology develops, AI-driven diagnostic tools will become more and more important for the timely and accurate diagnosis of cancer, opening the door to more potent therapies and higher survival rates.

5. Treatment

The application of artificial intelligence (AI), machine learning (ML), and deep learning (DL) in cancer treatment has transformed traditional approaches, offering personalized, efficient, and more effective therapeutic options. These technologies play a crucial role in various aspects of treatment, including planning, execution, and monitoring. This section explores the applications, benefits, and challenges of AI, ML, and DL in cancer treatment.

5.1. Personalized treatment plans

5.1.1. Definition and Scope

Personalized treatment plans involve tailoring medical care to the individual characteristics of each patient, such as their genetic profile, lifestyle, and specific characteristics of their cancer. AI and ML facilitate the creation of these personalized plans by analyzing vast amounts of patient data to determine the most effective treatments.

5.1.2. Applications

- **Genomic Analysis:** AI algorithms analyze genomic data to identify mutations and alterations that drive cancer growth. This information guides the selection of targeted therapies that are specific to the patient's genetic profile.
- **Predictive Modeling:** ML models predict how patients will respond to different treatments based on their genetic and molecular profiles. This helps oncologists choose the most effective therapy while minimizing side effects.
- **Drug Response Prediction:** DL models analyze clinical trial data and patient records to predict responses to new or existing drugs. This aids in the development of personalized treatment regimens.

5.1.3. Benefits

- **Targeted Therapies:** This results in the ability to establish individual treatment using targeted therapies that have an impact on tumor cells without having an adverse effect on healthy cells, enhancing outcomes and minimizing the side effects.
- **Optimized Treatment:** Artificial intelligence analysis also aids in developing the best care plan regarding the peculiarities of the patient's cancer.
- **Efficient Decision-Making:** Machine learning helps obtain objective information for oncologists, which saves time to make a decision.

5.1.4. Challenges

- **Data Complexity:** Identifying objects, genotypes, and the relationships between them and the interactions of molecules involves complicated formulas and extensive computation.
- **Data Privacy**: The preservation of the patient's genetic data is quite important because this information is normally considered sensitive.
- **Access to Technology:** The inequality in cancer care cannot be experienced if equal access to AI-driven personalized medicine tools is not made possible.

5.2. Radiation Therapy

5.2.1. Definition and Scope

I will brief you on radiation therapy, which entails using high-energy radiation in a bid to either kill the cancerous cells or, in a way, slow their growth. DL and AI both improve the accuracy and efficacy of using radiation therapy while planning its application and administering it to the patient.

5.2.2. Applications

- **Treatment Planning:** In radiation treatment, an AI algorithm seeks the best plan for giving the required amount of radiation to cancer cells while keeping the harm to healthy tissue as low as possible.
- **Image-Guided Radiation Therapy (IGRT):** DL models use the imaging data to provide real-time imaging guidance on the treatment planning of delivering radiation on a tumor.
- **Adaptive Radiation Therapy:** Coping with the process of radiation, the size and position of a tumor change in the course of the therapy as AI systems modify the given radiation plans.

5.2.3. Benefits

- **Precision:** Treatment planning through the use of AI enhances the accuracy of radiation delivery, thus minimizing the adverse effects on the patient's health while boosting the effectiveness of the treatment.
- **Real-Time Adjustments:** Real-time adaptation to radiation is possible using the DL models; thus, the tumor can be effectively targeted even if it shifts or changes its size.
- **Improved Outcomes:** This makes the optimized radiation therapy plans to control the tumor better and, at the same time, minimize complications.

5.2.4. Challenges

- **Integration:** Incorporation of the AI tools into the current radiation therapy management processes involves modifications of chemistries and also professional development of the human-wheel personnel.
- **Data Quality:** imaging data quality significantly impacts the AI model's accuracy; the data can differ between various machines and institutions.
- **Cost:** Some of the factors that make the radiation therapy systems that apply artificial intelligence costly.

5.3. Chemotherapy and Drug Development

5.3.1. Definition and Scope

Chemotherapy is a treatment that aims at identifying drugs that would remove cancer cells or prevent their further growth. AI and ML complement chemotherapy through the provision of prognosis on drug reactions, the determination of the appropriate dosage, and the speeding up of the drug discovery process.

5.3.2. Applications

- **Drug Response Prediction:** Deep learning techniques are applied to develop predictive models of patients' reactions to chemotherapeutic agents for better options advised by oncologists.
- **Dosing Optimization:** Other applications of ML are in selecting the most appropriate treatment schedules for chemotherapy and their combinations depending on the body characteristics and treatment response, which reduces side effects and enhances effectiveness.
- **Drug Discovery:** DL models process a large set of chemical compounds and biological targets in order to develop new treatments for cancer. This shortens the time it takes to discover drugs and also helps to diminish the associated costs.

5.3.3. Benefits

- **Personalized Chemotherapy:** Smart predictions help to avoid general administration of chemotherapy doses and are directed to the patients' response level to enhance results and minimize harm.
- **Efficient Dosing:** Measures such as developing new schedules reduce toxicity and increase the efficacy of chemotherapy.
- **Accelerated Drug Discovery:** AI helps improve the chances of discovering molecules with promising characteristics faster, thus getting new treatments to patients faster.

5.3.4. Challenges

- **Model Validation:** It is vital to guarantee that the AI models are precise and dependable in foreseeing drug responses and the right dosing regimens.
- **Data Integration:** It has been noted that the integration of multiple types of data, including genomic, clinical, pharmacological, etc., may be an issue when it comes to their usage in AI models.
- **Regulatory Approval:** New methods in drug development using artificial intelligence are also a major issue; regulatory approval is a long process since new methods need validation and clinical trials.

5.4. Immunotherapy

5.4.1. Definition and Scope

Immunotherapy is a technique by which the body's immune system is used to combat cancer. AI and ML improve immunotherapy through the determination of biomarkers that may signal responses and the improvement of the approaches used to administer treatment.

5.4.2. Applications

- **Biomarker Identification:** Machine learning models learn from genomic and proteomic genotypes and deliver biomarkers essential to a patient's reaction to immunotherapy.
- **Treatment Optimization**: It enhances immunotherapy because it uses ML concepts to analyze patient data and determine the best course of action by predicting a patient's response to immunotherapy regimens.
- **Clinical Trial Matching**: IT solutions help to link patients with appropriate clinical trials according to their genes and molecular characteristics and, thereby, bring more people to advanced treatment options.

5.4.3. Benefits

- **Enhanced Efficacy**: Thus, biomarker identification leveraging AI assists in choosing the patients who are likely to benefit from immunotherapy most of the time, enhancing the effectiveness of the treatment.
- **Personalized Strategies**: Corresponding patterns of immunotherapeutic regimens improve immunotherapy since the treatment procedure involves focusing on the patient's response.
- **Increased Access**: AI systems enable patient registration for trials to gain access to innovative immunotherapies.

5.4.4. Challenges

- **Complexity**: It is therefore extremely difficult to accurately model AI due to the complicated nature of immune responses as well as the differences in patients' responses to the medications.
- **Ethical Considerations**: Thus, eradicating AI-based immunotherapy approaches' misuse and promoting their transparency is critical for continued patient confidence.
- **Data Integration**: Applying various data, including genomic, proteomic, and clinical data, to create AI models is a complex process that necessitates unique algorithms and computational capabilities.

With the help of AI, ML, and DL technologies, it is possible to provide patients with individual, targeted, and effective treatment for cancer. They refine patient care plans, offer the best radiation treatment, increase the effectiveness of chemotherapy, boost immunotherapy, and ensure positive patient results. However, several issues associated with data handling, model substantiation, and technology implementation in clinical settings still remain unsolved in order to optimize the capacities of these technologies. In the future, therefore, the direct clinical application of research and development in AI for treating cancer is likely to be of great significance in the oncology field, as it will change the face of cancer treatment by improving survivability.

6. Challenges and Future Directions

Incorporation of AI, ML, and DL in different aspects of cancer will be a blessing and a curse depending on how it is implemented. Mitigating all these risks and charting the future course is therefore a critical importance as it relates to the optimization of these technologies in oncology.

6.1. Challenges

6.1.1. Data Quality and Accessibility

- **Challenge**: AI models depend on big datasets and the quality of data used in the testing of models. The primary issue regarding big data in the healthcare system is the correct, complete, and easily accessible data across varying healthcare systems and medical facilities.
- **Impact:** If data is unclean then this is propagated in the decision making system of the AI and might harm patient care and results.

6.1.2. Interpretability of AI Models:

- **Challenge:** DL models especially the deep ones, are usually large and convoluted and clinicians will often find it hard to understand how an outcome was arrived at.
- **Impact:** Lack of interpretability of results could lead to less trust and, therefore, less acceptance of the Ai-based recommendations if integrated in clinical practice.

6.1.3. Ethical and Regulatory Considerations:

- **Challenge**: Some ethical questions relate to levels of patients' privacy and security, impact of the AI algorithm's choice on each patient, and the applicability of AI in the healthcare domain.
- **Impact:** The existing policies and laws have to be adapted in a way that will protect patients and the public from risks posed by the technology, be fair and be accountable for the use of AI.

6.1.4. Integration into Clinical Workflows:

- **Challenge:** Implementing AI into clinical care means modifications to infrastructure, alterations in how work processes are carried out in clinical space, and education of the health care workforce.
- **Impact:** Some of the challenges faced in the implementation of AI technologies include: Inadequate resources and funds Slow adoption of the technologies due to resistance to change Logistical challenges that would hinder the adoption and implementation of the new technologies.

6.1.5. Generalizability and Validation:

- **Challenge:** Some AI models may perform well on specific data set and fail to do well when tested on different patient cohort or different clinical environment.
- **Impact:** AI models need to be accurate and reliable for different people and regions to be applicable widely and efficient.

6.1.6. Cost and Resource Allocation:

- **Challenge:** Many technologies categorized under artificial intelligence will incur additional yearly expenses for medical settings through infrastructure, hardware, and learning.
- **Impact:** It assesses the likelihood of facing disparities by using AI in cancer care, thus influencing equitable healthcare distribution and the patients' experience.

6.2. Future Directions

6.2.1. Enhancing Data Infrastructure:

Improving data collection, standardization, and interoperability across healthcare systems to ensure high-quality data for AI model development and validation.

Promoting data sharing initiatives and collaborations to leverage diverse datasets for training robust and generalizable AI models.

6.2.2. Advancing AI Model Interpretability

Developing methods to enhance transparency and interpretability of AI algorithms, enabling clinicians to understand and trust AI-driven recommendations.

Integrating explainable AI techniques that provide insights into how decisions are made, enhancing accountability and acceptance in clinical practice.

6.2.3. Ethical Guidelines and Governance

Establishing clear ethical guidelines and regulatory frameworks for the development, deployment, and evaluation of AI technologies in oncology.

Addressing issues of bias, fairness, privacy, and patient consent to ensure ethical use of AI and protect patient rights and welfare.

6.2.4. Integration and Adoption in Healthcare

Facilitating seamless integration of AI tools into clinical workflows through user-friendly interfaces, interoperable systems, and continuous education and training for healthcare professionals.

Collaborating with clinicians, researchers, and industry stakeholders to pilot and evaluate AI applications in real-world healthcare settings.

6.2.5. Personalized Medicine and Precision Oncology

Advancing AI-driven approaches to personalize cancer treatment based on individual patient characteristics, including genomic profiles, biomarkers, and treatment responses.

Harnessing AI to optimize treatment planning, predict treatment outcomes, and identify novel therapeutic targets for precision oncology.

6.2.6. Global Access and Equity

Promoting equitable access to AI-driven cancer care by addressing disparities in technology adoption, resource allocation, and healthcare infrastructure.

Supporting initiatives that enhance access to AI technologies in low-resource settings and underserved populations, ensuring that all patients benefit from advancements in oncology.

The challenges and future directions of AI, ML, and DL in cancer care underscore the need for collaborative efforts across disciplines and regions. Addressing data quality, interpretability, ethical considerations, integration into clinical workflows, validation, cost-effectiveness, and global access are essential for realizing the full potential of these technologies in improving cancer diagnosis, treatment, and outcomes. As research continues and technological advancements evolve, AI-driven innovations hold promise for transforming oncology and delivering personalized, effective, and equitable cancer care worldwide.

7. Conclusion

Artificial intelligence (AI), machine learning (ML), and deep learning (DL) in the field of oncology have become the new way of approaching cancer diagnosis, cancer treatment, and cancer control. These technologies provide a virtually unlimited measure of potential to process large volumes of information during the diagnosis and create effective treatment programs based on medical images and genomic profiles, the results of the treatments, etc., allowing oncologists to be more comprehensive as to the options and the approach chosen based on the patient's features. Clinicians now use artificial intelligence techniques to forecast the diseases' development, choose therapy strategies, and fine-tune the therapeutic procedures better than before.

Third, AI improves early detection, thus improving the outcomes of cancer. The modern computational methods will be able to analyze the data and find the patterns and biomarkers of cancer in the initial stage, which will enable health care administrators to prevent the occurrence of cancer in its late stages, which will enhance the chances of survival. It is most effective in its ability to reveal those people at risk and the preventative interventions that might slow the advancement of disease.

However, there are several problems that have been culminating in the integration of AI in clinical practice. There are also preeminent challenges, including challenges with data quality, challenges with how the AI systems will harmonize with the existing systems in the health setting, and more to do with ethical concerns about patient privacy and reasons why the algorithms have to be transparent. To tackle these concerns, collaborative approaches from both clinicians, researchers, policymakers, and technology innovators are crucial to enforcing the appropriate use of AI technologies within clinical settings that can benefit patients, as well as protecting patients' safety and rights involved in these processes.

The prospects of utilizing AI in oncology in the future are quite encouraging for the development of the concept of precision medicine and patient-tailored treatments. Future advancements and studies will most probably result in improved AI algorithms that could interpret various data sets and identify an individual's response to a treatment with even higher rates of efficiency. Therefore, future developments of AI in oncology can significantly transform cancer care, suggesting ways of improving the quality of life for patients and ensuring that this condition is approaching being treated worldwide.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Gaur, K., & Jagtap, M. M. (2022). Role of artificial intelligence and machine learning in prediction, diagnosis, and prognosis of cancer. Cureus, 14(11).

[2] Tran, K. A., Kondrashova, O., Bradley, A., Williams, E. D., Pearson, J. V., & Waddell, N. (2021). Deep learning in cancer diagnosis, prognosis and treatment selection. Genome Medicine, 13, 1-17.

[3] Iqbal, M. J., Javed, Z., Sadia, H., Qureshi, I. A., Irshad, A., Ahmed, R., ... & Sharifi-Rad, J. (2021). Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future. Cancer cell international, 21(1), 270.

[4] Sultan, A. S., Elgharib, M. A., Tavares, T., Jessri, M., & Basile, J. R. (2020). The use of artificial intelligence, machine learning and deep learning in oncologic histopathology. Journal of Oral Pathology & Medicine, 49(9), 849-856.

[5] Allegra, A., Tonacci, A., Sciaccotta, R., Genovese, S., Musolino, C., Pioggia, G., & Gangemi, S. (2022). Machine learning and deep learning applications in multiple myeloma diagnosis, prognosis, and treatment selection. Cancers, 14(3), 606.

[6] Qazi, S., Iqbal, N., & Raza, K. (2021). Machine learning in cancer diagnosis, prognosis and therapy. Artif Intell Data-Driven Med Diagnosis, 3, 103.

[7] Huang, S., Yang, J., Fong, S., & Zhao, Q. (2020). Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges. Cancer letters, 471, 61-71.

[8] Chugh, G., Kumar, S., & Singh, N. (2021). Survey on machine learning and deep learning applications in breast cancer diagnosis. Cognitive Computation, 13(6), 1451-1470.

[9] Pei, Q., Luo, Y., Chen, Y., Li, J., Xie, D., & Ye, T. (2022). Artificial intelligence in clinical applications for lung cancer: diagnosis, treatment and prognosis. Clinical Chemistry and Laboratory Medicine (CCLM), 60(12), 1974-1983.

[10] Chen, Z. H., Lin, L., Wu, C. F., Li, C. F., Xu, R. H., & Sun, Y. (2021). Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine. Cancer Communications, 41(11), 1100-1115.

[11] Elemento, O., Leslie, C., Lundin, J., & Tourassi, G. (2021). Artificial intelligence in cancer research, diagnosis and therapy. Nature Reviews Cancer, 21(12), 747-752.

[12] Kourou, K., Exarchos, K. P., Papaloukas, C., Sakaloglou, P., Exarchos, T., & Fotiadis, D. I. (2021). Applied machine learning in cancer research: A systematic review for patient diagnosis, classification and prognosis. Computational and Structural Biotechnology Journal, 19, 5546-5555.

[13] Pettit, R. W., Fullem, R., Cheng, C., & Amos, C. I. (2021). Artificial intelligence, machine learning, and deep learning for clinical outcome prediction. Emerging topics in life sciences, 5(6), 729-745.

[14] Liang, F., Wang, S., Zhang, K., Liu, T. J., & Li, J. N. (2022). Development of artificial intelligence technology in diagnosis, treatment, and prognosis of colorectal cancer. World Journal of Gastrointestinal Oncology, 14(1), 124.

[15] Tătaru, O. S., Vartolomei, M. D., Rassweiler, J. J., Virgil, O., Lucarelli, G., Porpiglia, F., ... & Ferro, M. (2021). Artificial intelligence and machine learning in prostate cancer patient management—current trends and future perspectives. Diagnostics, 11(2), 354.

[16] Alhasan, A. S. (2021). Clinical applications of artificial intelligence, machine learning, and deep learning in the imaging of gliomas: a systematic review. Cureus, 13(11).

[17] Nayak, J., Favorskaya, M. N., Jain, S., Naik, B., & Mishra, M. (2021). Advanced machine learning approaches in cancer prognosis. Springer International Publishing.

[18] Gupta, S., & Kumar, Y. (2022). Cancer prognosis using artificial intelligence-based techniques. SN Computer Science, 3(1), 77.

[19] Zhu, W., Xie, L., Han, J., & Guo, X. (2020). The application of deep learning in cancer prognosis prediction. Cancers, 12(3), 603.

[20] Coccia, M. (2020). Deep learning technology for improving cancer care in society: New directions in cancer imaging driven by artificial intelligence. Technology in Society, 60, 101198.

[21] Hanefi Calp, M. (2021). Use of deep learning approaches in cancer diagnosis. Deep learning for cancer diagnosis, 249-267.

[22] Hunter, B., Hindocha, S., & Lee, R. W. (2022). The role of artificial intelligence in early cancer diagnosis. Cancers, 14(6), 1524.

[23] Kumar, S. (2019). Importance of Artificial Intelligence–Machine Learning & Deep Learning Prediction in Cancer Diagnosis using Logistic Regression. Int. J. Mod. Trends Sci. Technol., 5, 17-22.

[24] Jiang, Y., Yang, M., Wang, S., Li, X., & Sun, Y. (2020). Emerging role of deep learning-based artificial intelligence in tumor pathology. Cancer communications, 40(4), 154-166.

[25] Razek, A. A. K. A., Khaled, R., Helmy, E., Naglah, A., AbdelKhalek, A., & El-Baz, A. (2022). Artificial intelligence and deep learning of head and neck cancer. Magnetic Resonance Imaging Clinics, 30(1), 81-94.

[26] Dixit, S., Kumar, A., & Srinivasan, K. (2023). A current review of machine learning and deep learning models in oral cancer diagnosis: Recent technologies, open challenges, and future research directions. Diagnostics, 13(7), 1353.

[27] Li, Y., Wu, X., Yang, P., Jiang, G., & Luo, Y. (2022). Machine learning for lung cancer diagnosis, treatment, and prognosis. Genomics, Proteomics and Bioinformatics, 20(5), 850-866.

[28] Sadeeq, H. T., Ameen, S. Y., & Abdulazeez, A. M. (2022, November). Cancer Diagnosis based on Artificial Intelligence, Machine Learning, and Deep Learning. In 2022 International Conference on Innovation and Intelligence for Informatics, Computing, and Technologies (3ICT) (pp. 656-661). IEEE.

[29] Murthy, N. S., & Bethala, C. (2023). Review paper on research direction towards cancer prediction and prognosis using machine learning and deep learning models. Journal of Ambient Intelligence and Humanized Computing, 14(5), 5595-5613.

[30] Zhang, H., Xi, Q., Zhang, F., Li, Q., Jiao, Z., & Ni, X. (2023). Application of deep learning in cancer prognosis prediction model. Technology in Cancer Research & Treatment, 22, 15330338231199287.

[31] Golden, J. A. (2017). Deep learning algorithms for detection of lymph node metastases from breast cancer: helping artificial intelligence be seen. Jama, 318(22), 2184-2186.

[32] Rabaan, A. A., Bakhrebah, M. A., AlSaihati, H., Alhumaid, S., Alsubki, R. A., Turkistani, S. A., ... & Mutair, A. A. (2022). Artificial intelligence for clinical diagnosis and treatment of prostate cancer. Cancers, 14(22), 5595.

[33] Pérez, M. J., & Grande, R. G. (2020). Application of artificial intelligence in the diagnosis and treatment of hepatocellular carcinoma: A review. World journal of gastroenterology, 26(37), 5617.

[34] Goldenberg, S. L., Nir, G., & Salcudean, S. E. (2019). A new era: artificial intelligence and machine learning in prostate cancer. Nature Reviews Urology, 16(7), 391-403.

[35] Levine, A. B., Schlosser, C., Grewal, J., Coope, R., Jones, S. J., & Yip, S. (2019). Rise of the machines: advances in deep learning for cancer diagnosis. Trends in cancer, 5(3), 157-169.

[36] Sufyan, M., Shokat, Z., & Ashfaq, U. A. (2023). Artificial intelligence in cancer diagnosis and therapy: Current status and future perspective. Computers in Biology and Medicine, 107356.

[37] Sudhi, M., Shukla, V. K., Shetty, D. K., Gupta, V., Desai, A. S., Naik, N., & Hameed, B. Z. (2023). Advancements in bladder cancer management: a comprehensive review of artificial intelligence and machine learning applications. Engineered Science, 26(2), 1003.

[38] Koh, D. M., Papanikolaou, N., Bick, U., Illing, R., Kahn Jr, C. E., Kalpathi-Cramer, J., ... & Prior, F. (2022). Artificial intelligence and machine learning in cancer imaging. Communications Medicine, 2(1), 133.

[39] Bakrania, A., Joshi, N., Zhao, X., Zheng, G., & Bhat, M. (2023). Artificial intelligence in liver cancers: Decoding the impact of machine learning models in clinical diagnosis of primary liver cancers and liver cancer metastases. Pharmacological research, 189, 106706.

[40] Yin, Z., Yao, C., Zhang, L., & Qi, S. (2023). Application of artificial intelligence in diagnosis and treatment of colorectal cancer: A novel Prospect. Frontiers in Medicine, 10, 1128084.